U.S. Consumer Durables Stock News

Millicom International Cellular S.A. recently announced its third quarter 2025 earnings, reporting quarterly sales of US$1.42 billion and net income of US$195 million, both compared against the same period last year. Net income and earnings per share increased very substantially year-over-year, reflecting the influence of completed acquisitions and operational progress across new markets. We'll explore how the sharp growth in net income and enhanced earnings quality may influence Millicom's...

Middleby (MIDD) is in the spotlight after posting third-quarter results that beat expectations. The company lifted its full-year outlook and launched a strategic review of its Residential Kitchen business following a sizable impairment charge. See our latest analysis for Middleby. After a volatile year, Middleby’s recent strategic moves and stronger Q3 results have caught the market’s eye, but these changes have not turned around its longer-term trajectory. The stock’s one-year total return...

Kaspi.kz (NasdaqGS:KSPI) has just released its third quarter and year-to-date 2025 earnings, showing a marked increase in revenue compared to the previous year. This latest financial update is drawing investor attention. See our latest analysis for Kaspi.kz. Kaspi.kz’s solid earnings have landed just as the stock has seen some sharp swings. The year-to-date share price return sits at -26.05%, while the total shareholder return over the past year is down 33.25%. Momentum remains challenged,...

Akebia Therapeutics (AKBA) just posted third quarter 2025 earnings, swinging from a net loss to net profit as a result of much higher revenue. Investors are watching closely because this marks a financial turnaround for the company. See our latest analysis for Akebia Therapeutics. Akebia’s share price has taken a hit recently. Even after swinging to profit this quarter, it fell 18% in the past day and is down 39% over the last month as investors digested mixed clinical trial updates and...

Citigroup recently expanded its Citi Token Services platform to support Euro transactions, extending operations to Dublin, Ireland and further broadening its global, real-time cross-border payment capabilities for corporate and institutional clients. This move marks a key advance in Citigroup's digital asset strategy, combining enhanced liquidity with ongoing investments in artificial intelligence and technological innovation. We’ll now explore how the launch of Euro-enabled Citi Token...

Alexander's, Inc. recently reported third-quarter earnings, noting sales of US$53.42 million and net income of US$5.97 million, both lower than the prior year's results, and reaffirmed a quarterly dividend of US$4.50 per share payable later this month. Despite these year-over-year declines in sales and earnings, strong analyst sentiment has led to an upward revision in full-year earnings estimates and elevated the company to a top ranking by Zacks. We'll examine how the improved analyst...

Dianthus Therapeutics (DNTH) caught investor attention after announcing statistically significant positive results from its Phase 2 trial for claseprubart in generalized myasthenia gravis. The company now plans to launch Phase 3 studies. See our latest analysis for Dianthus Therapeutics. The market has clearly taken notice of Dianthus Therapeutics’ recent milestones. The share price is up nearly 84% over the past 90 days, and there has been a robust year-to-date increase of 58% following...

Rithm Capital Corp. recently reported earnings for the six months ended September 30, 2025, posting net income of US$221.54 million with basic earnings per share from continuing operations of US$0.36. Although the company highlighted strong results, it also disclosed substantial acquisition integration risks and insider share sales, raising questions about upcoming challenges and executive confidence. We'll now explore how the integration risks from recent acquisitions may shape Rithm...

Microvast Holdings (MVST) just released its third quarter results, highlighting a jump in sales and a sharp reduction in year-to-date net losses. Investors are watching closely to see how these numbers influence momentum. See our latest analysis for Microvast Holdings. The latest earnings news comes on the heels of an impressive run for Microvast Holdings, as the 1-year total shareholder return stands at a staggering 2,455%. After some recent volatility and a sharp 7-day pullback, the 90-day...

Cellebrite DI (CLBT) has been attracting interest given its recent share movement and the company's evolving position in digital intelligence solutions. Investors have noticed the stock’s mixed performance over the past month and year, which is driving conversation about future prospects. See our latest analysis for Cellebrite DI. Momentum around Cellebrite DI has seen its ups and downs, with a sharp 18.3% dip in the past month hinting at shaken confidence. However, the company’s longer-term...

Tyson Foods (TSN) shares have been on investors’ radars recently, especially as the stock’s returns over the past month show a modest recovery. For those interested in the food sector, the company’s recent performance raises interesting questions about its value and future prospects. See our latest analysis for Tyson Foods. Tyson Foods has seen a modest rebound lately, with a 4.4% 7-day share price return adding to positive momentum after a weak first quarter. Despite recent gains, the...

IRADIMED CORPORATION recently reported third quarter and nine-month 2025 results, revealing year-over-year growth in revenue and net income, and raised its full-year 2025 revenue and earnings guidance. The company’s ability to lift full-year projections after another period of double-digit sales growth highlights management’s confidence in ongoing demand for its MRI-compatible medical devices. We’ll explore how IRADIMED’s raised guidance could influence its long-term growth narrative and...

Invesco Ltd. recently reported third quarter results, showing significant year-over-year growth in both revenue and net income, alongside a new share repurchase update and quarterly dividend affirmations for both common and preferred shareholders. The company also indicated an ongoing focus on mergers and acquisitions in private markets, highlighting $130 billion in assets and future growth ambitions in this segment. We'll explore how this strong earnings growth and expanding private markets...

Wondering if W. P. Carey is still a bargain or if its recent run means you might be late to the party? You're not alone. Knowing whether to buy, hold, or move on all starts with nailing down what the stock is really worth. After a solid 27.2% gain over the last year and a jump of 23.2% year-to-date, W. P. Carey's stock clearly hasn't gone unnoticed, with buyers and risk-takers eyeing the momentum. Some of the recent uptick can be traced to sector-wide moves in commercial real estate and...

The FDA’s recent approval for a label update on CARVYKTI, Legend Biotech (LEGN)’s flagship therapy, highlights promising survival benefits for patients with relapsed, refractory multiple myeloma. This regulatory milestone could influence the company's future outlook. See our latest analysis for Legend Biotech. Legend Biotech’s latest FDA win for CARVYKTI appears to have injected some confidence into the long-term story. However, short-term share price returns tell a more muted tale, with the...

Integer Holdings (ITGR) just revealed a major update for its investors, announcing a share buyback program of up to $200 million. The program will be funded mainly by available cash and free cash flow. This move is likely to catch the market’s attention given its scale and funding approach. See our latest analysis for Integer Holdings. Integer Holdings’ buyback announcement lands after a challenging stretch, with the share price down nearly 32% in the last month and a year-to-date price...

Zevra Therapeutics (ZVRA) just released its third quarter and nine-month earnings results, reporting major improvements in sales and profitability compared to last year. Investors are taking notice because the company has made a significant financial turnaround. See our latest analysis for Zevra Therapeutics. After a remarkable swing in its earnings fortunes, Zevra Therapeutics’ short-term share price has seen a mix of volatility and modest gains, with a 1-year total shareholder return of...

Gentex (GNTX) just announced a new carbon fiber automatic-dimming rearview mirror tailored for custom cars, introduced in partnership with Ringbrothers at the SEMA show. The event also featured custom vehicle unveils showcasing Gentex’s advanced technology. See our latest analysis for Gentex. Gentex's share price recently slipped to $23.31, reflecting a 1-year total shareholder return of -21.24%. While the unveiling of high-profile products at SEMA highlights its innovative edge, recent...

Super Micro Computer reported disappointing first-quarter results for fiscal 2026, with sales of US$5.02 billion and net income of US$168.29 million, both down from the same period last year, but raised its full-year guidance to at least US$36 billion in net sales, citing strong demand and a record order backlog. The company also launched a new federal-focused subsidiary and showcased advanced AI infrastructure solutions tailored for government, reflecting a continued push to expand its US...

Ever wondered if Carlyle Group is a bargain or overhyped in today's market? You're not alone. This is a question lots of investors are asking right now. After rallying more than 100% over the past three years, the stock has cooled off, returning just 1.8% in the last year and dipping 6.5% in the past month. Much of this recent movement has been driven by shifting investor sentiment around private equity, with news of increased fundraising activity and changes in capital flows drawing more...

Travere Therapeutics (TVTX) just released new findings from its Phase 3 DUPLEX Study, showing that FILSPARI treatment helped FSGS patients achieve meaningful reductions in proteinuria compared to the existing standard of care. See our latest analysis for Travere Therapeutics. The excitement from Travere’s Phase 3 DUPLEX Study update comes after a robust rally for the stock, as the one-month share price return surged 36.7% and the 90-day gain climbed to an impressive 90.5%. Adding to the...

Medical Properties Trust, Inc. recently announced a share repurchase program, authorizing the buyback of up to US$150 million worth of its common shares. This move comes as the company addresses ongoing challenges with tenant financial health and asset quality following high-profile tenant bankruptcies. We'll examine how the share buyback program could signal management's confidence and reshape Medical Properties Trust's investment narrative. The latest GPUs need a type of rare earth metal...

Penguin Solutions, Inc. recently announced its participation at Supercomputing 25 (SC25) in St. Louis, where it will showcase breakthrough AI infrastructure technologies and highlight its partnership with SK Telecom supporting a major AI factory in South Korea. In addition, Penguin Solutions announced general availability of Oracle Linux on its Stratus ztC Endurance platforms, enabling highly reliable operation of critical enterprise applications with extremely low downtime. We will explore...

Wondering if American Airlines Group is really a bargain or just looks cheap on the surface? You are not alone, and this could be the perfect time to look under the hood. The stock has climbed 15.5% in the past 30 days, yet is still down 21.7% year-to-date, making for an intriguing setup for investors weighing recent momentum against longer-term challenges. Headlines recently have highlighted American Airlines' strategic updates around its network and ongoing operational...